Literature DB >> 26247460

Leukostasis Retinopathy: A New Clinical Manifestation of Chronic Myeloid Leukemia With Severe Hyperleukocytosis.

Caroline C Awh, John B Miller, David M Wu, Dean Eliott.   

Abstract

The authors report a new clinical manifestation of chronic myeloid leukemia. A 41-year-old man presented with significant visual loss, leading to a diagnosis of chronic myeloid leukemia. His white blood count exceeded that of any previously reported case of the disease with documented retinal findings (562,000/mm(3)), and clinical evaluation revealed the blockage of temporal retinal vessels by white blood cells. Hematologic findings resolved within 1 month of chemotherapy with dasatinib, and further treatment with intravitreal anti-VEGF agents resulted in the complete resolution of fundus findings. The authors propose that leukostasis retinopathy be recognized as a clinical manifestation of this life-threatening disease. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26247460     DOI: 10.3928/23258160-20150730-14

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  3 in total

1.  A quantitative comparison of five optical coherence tomography angiography systems in clinical performance.

Authors:  Xin-Xin Li; Wei Wu; Hao Zhou; Jun-Jie Deng; Meng-Ya Zhao; Tian-Wei Qian; Chen Yan; Xun Xu; Su-Qin Yu
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

2.  Ocular Manifestations of Leukemia and Results of Treatment with Intravitreal Methotrexate.

Authors:  Vicktoria Vishnevskia-Dai; Sara Sella King; Ruth Lekach; Ido Didi Fabian; Ofira Zloto
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

Review 3.  Leukostasis retinopathy: An uncommon visual threatening complication of chronic myeloid leukemia with severe hyperleukocytosis - A case report and review of the literature.

Authors:  Bo Chen; Xiaoqin Yan; Xian Zhang; Hong Yang
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.